India Pharma Outlook and Latest News – Pharmaceutical Industry in India
India’s pharmaceutical industry is one of the world’s largest, ranking third globally by volume and 14th by value, with a market valued at approximately $60 billion. Known as the “Pharmacy of the World,” India provides around 40% of the generic medicines consumed in the United States and produces more than 50% of the world’s vaccines.
The Indian pharma sector is projected to grow 9–11% in FY2026, driven by strong domestic demand of 8–10% and robust European market expansion of 15–17%, while US growth slows to 4–6% due to price erosion and regulatory challenges. Operating profit margins remain stable at 24–25% supported by favorable raw material costs and rising specialty product share, with R&D spending at 6–7% of revenues focused on complex molecules and innovation. The industry is transitioning from volume-led supply to value-driven global partnerships, moving from “World’s Pharmacy” to “World’s Innovation Partner,” as exports hit a record $30+ billion in FY25 (+9.4% over FY24). With $250 billion worth of innovator drugs going off patent over the next 5 years, significant opportunities exist for generics and complex products, backed by government support of Rs. 5,268 crore for the Department of Pharmaceuticals and GST exemptions on select medicines.
India Pharma Monitor is designed as a centralized platform to track these developments efficiently. It curates key updates across regulatory changes, market trends, export activity, research advancements, and industry movements in a structured format. The aim is to offer readers a clear and reliable overview of the Indian pharmaceutical landscape, enabling quicker insights, easier comparison, and better-informed understanding of the sector.
Latest Pharma News
Follow the latest pharma news from India and the wider pharmaceutical industry. This section highlights major headlines, breaking developments, and important daily updates.
-
Strides Pharma Receives Three Remarks From USFDA After Inspecting Alathur Facility
Strides Pharma Receives Three Remarks From USFDA After Inspecting Alathur Facility Sahi
-
Dr. Reddy’s Labs Receives Two USFDA Observations For Mexico API Facility Records Assessment
Dr. Reddy’s Labs Receives Two USFDA Observations For Mexico API Facility Records Assessment Sahi
-
Experts Call for Deeper Industry-Academia Collaboration to Drive India's Biopharma
Experts Call for Deeper Industry-Academia Collaboration to Drive India's Biopharma Siliconindia
-
Endometriosis Market Analysis 2036: Industry Trends, Market Size, and Emerging Therapeutic Developments – DelveInsight | AbbVie, Kissei Pharma, Theramex, Hope Medicine, TiumBio, Viramal, Organon
Endometriosis Market Analysis 2036: Industry Trends, Market Size, and Emerging Therapeutic Developments – DelveInsight | AbbVie, Kissei Pharma, Theramex, Hope Medicine, TiumBio, Viramal, Organon Barchart.com
-
GSK to shut vaccine factory in Germany, putting 641 jobs at risk
GSK to shut vaccine factory in Germany, putting 641 jobs at risk ETHRWorld.com
Regulatory Updates
Track pharmaceutical regulatory updates, policy changes, and compliance-related news. This section is useful for staying informed about approvals, guidelines, and official announcements.
-
Chronic Hepatitis B Market Statistics Expected to Experience Major Growth by 2034, According to DelveInsight | Gilead Sciences, GlaxoSmithKline, Ionis Pharma, Precision Biosciences, Silverback Thera
Chronic Hepatitis B Market Statistics Expected to Experience Major Growth by 2034, According to DelveInsight | Gilead Sciences, GlaxoSmithKline, Ionis Pharma, Precision Biosciences, Silverback Thera Barchart.com
-
India-UK CETA Could Put Maharashtra At The Centre Of Healthcare Investment
India-UK CETA Could Put Maharashtra At The Centre Of Healthcare Investment BW Healthcare World
-
Glenmark launches allergic rhinitis nasal spray Ryaltris in Brazil
Glenmark launches allergic rhinitis nasal spray Ryaltris in Brazil pharma.economictimes.indiatimes.com
-
BetterLife Pharma Inc. Announces Filing of Final Prospectus for US$100 Million Public Offering of Common Shares and Pre-Funded Warrants
BetterLife Pharma Inc. Announces Filing of Final Prospectus for US$100 Million Public Offering of Common Shares and Pre-Funded Warrants TradingView
-
Scholar Rock wins FDA approval for first drug to target SMA muscle loss
Scholar Rock wins FDA approval for first drug to target SMA muscle loss STAT
Drug Approvals
Read about new drug approvals, product clearances, and important authorisations. This section covers medicines entering the market and other notable approval milestones.
-
Endometriosis Market Analysis 2036: Industry Trends, Market Size, and Emerging Therapeutic Developments – DelveInsight | AbbVie, Kissei Pharma, Theramex, Hope Medicine, TiumBio, Viramal, Organon
Endometriosis Market Analysis 2036: Industry Trends, Market Size, and Emerging Therapeutic Developments – DelveInsight | AbbVie, Kissei Pharma, Theramex, Hope Medicine, TiumBio, Viramal, Organon Barchart.com
-
Revolution Medicines (RVMD) Gets its First Approved Drug, and the Market Shrugs
Revolution Medicines (RVMD) Gets its First Approved Drug, and the Market Shrugs Yahoo Finance
-
FDA approves first-of-its-kind drug rusfertide for polycythemia vera
FDA approves first-of-its-kind drug rusfertide for polycythemia vera The Cancer Letter
-
5 August FDA Approvals Marked by Novelty, Pushback
5 August FDA Approvals Marked by Novelty, Pushback The American Journal of Managed Care
-
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON PR Newswire
Clinical and Research Updates
Explore clinical trial news, research findings, and developments in pharmaceutical science. This section focuses on innovation, studies, and progress in drug development.
-
Opinion: What we could gain from Cuba
Opinion: What we could gain from Cuba CT Mirror
-
AI-enabled clinical trials
AI-enabled clinical trials Bioengineer.org
-
Investigators at Emory University School of Medicine Zero in on Medical Education (Disability prevalence, disclosure, and accommodation use in pediatric residency: results from a pilot study): Education – Medical Education
Investigators at Emory University School of Medicine Zero in on Medical Education (Disability prevalence, disclosure, and accommodation use in pediatric residency: results from a pilot study): Education – Medical Education InsuranceNewsNet
-
Ministry Approves Risky COVID-19 Trial, Falls Short of 1960s FDA Standards
Ministry Approves Risky COVID-19 Trial, Falls Short of 1960s FDA Standards 조선일보
-
Video mental health care may have clinical advantages versus phone or in-person visits
Video mental health care may have clinical advantages versus phone or in-person visits 2 Minute Medicine
Industry Events
Discover pharma conferences, exhibitions, seminars, and industry events in India. This section helps readers keep track of sector gatherings and professional events.
-
Across four global innovation hubs: Insilico Medicine executive team to speak at premier healthcare and AI Summits
Across four global innovation hubs: Insilico Medicine executive team to speak at premier healthcare and AI Summits EurekAlert!
-
The Race for the Next Big Weight-Loss Drug Is On—and China Wants In | World News
The Race for the Next Big Weight-Loss Drug Is On—and China Wants In | World News Hindustan Times
-
Alembic Pharma clears USFDA inspection at Vadodara bioequivalence facility with nil observations
Alembic Pharma clears USFDA inspection at Vadodara bioequivalence facility with nil observations manufacturing.economictimes.indiatimes.com
-
Lubrizol to showcase drug delivery excipients at CPHI Milan
Lubrizol to showcase drug delivery excipients at CPHI Milan Manufacturing Chemist
-
Greenply Industries hosts investor meet at Anand Rathi summit
Greenply Industries hosts investor meet at Anand Rathi summit scanx.trade
Company Announcements
View company announcements including results, partnerships, expansions, and strategic updates. This section offers insights into the latest moves by pharma businesses.
-
MRK Banks on Growing Pipeline & New Drugs to Offset Keytruda LOE
MRK Banks on Growing Pipeline & New Drugs to Offset Keytruda LOE qz.com
-
Novartis shareholders step up scrutiny of deal strategy after del-desiran failure
Novartis shareholders step up scrutiny of deal strategy after del-desiran failure UA.NEWS
-
Singapore launches biotech-focused Boston hub to build on 'centuries-old bond'
Singapore launches biotech-focused Boston hub to build on 'centuries-old bond' Fierce Biotech
-
Rocket Lab Is Five Launches From 100 Electron Missions — Raymond James Flags Two Opportunities With ‘Significant Upsides’
Rocket Lab Is Five Launches From 100 Electron Missions — Raymond James Flags Two Opportunities With ‘Significant Upsides’ TradingView
Market and Sector Headlines
Stay informed on market trends, sector performance, and broader industry headlines. This section gives a wider view of the forces shaping the pharmaceutical market.
-
How Lower Medicaid Prices At Astellas Pharma Stock Has Changed Its Investment Story
How Lower Medicaid Prices At Astellas Pharma Stock Has Changed Its Investment Story simplywall.st
-
ETFs Investing in Yili Chuanning Biotechnology Co., Ltd. Class A Stocks
ETFs Investing in Yili Chuanning Biotechnology Co., Ltd. Class A Stocks TradingView
-
The Oral GLP-1 Tracker: Novo's Wegovy pill, Lilly's Foundayo continue prescription climb
The Oral GLP-1 Tracker: Novo's Wegovy pill, Lilly's Foundayo continue prescription climb Fierce Pharma
-
BioMarin Pharmaceutical (BMRN) Posts Phase 3 Win And FDA Filing In Hypochondroplasia
BioMarin Pharmaceutical (BMRN) Posts Phase 3 Win And FDA Filing In Hypochondroplasia simplywall.st
-
Revolution Medicines (RVMD) Gets its First Approved Drug, and the Market Shrugs
Revolution Medicines (RVMD) Gets its First Approved Drug, and the Market Shrugs Yahoo Finance
Policy and Government Initiatives
This section covers new regulations, industry support measures, and reforms that affect manufacturing, pricing, and compliance. It is also useful for following government schemes that encourage domestic production, exports, and research-led growth.
-
Healthcare Leaders Call For National Patient Charter
Healthcare Leaders Call For National Patient Charter BW Healthcare World
-
Nippon India Ultra Short to Short Term Fund-IDCW Quarterly (₹ 1,032.08) - NAV, Reviews & asset allocation
Nippon India Ultra Short to Short Term Fund-IDCW Quarterly (₹ 1,032.08) - NAV, Reviews & asset allocation The Economic Times
-
Invesco India Pharma And Healthcare Fund - Regular Plan Fund info
Invesco India Pharma And Healthcare Fund - Regular Plan Fund info The Economic Times
-
Invesco India Pharma And Healthcare Fund - Direct Plan Fund info
Invesco India Pharma And Healthcare Fund - Direct Plan Fund info The Economic Times
-
iPHEX 2026 sparks massive $4.5 billion–$5 billion in global business deals
iPHEX 2026 sparks massive $4.5 billion–$5 billion in global business deals Indian Pharma Post
Get the top pharma headlines every morning
One short email a day with the biggest stories in Indian and global pharma. Free, and you can unsubscribe any time.